Silver Book Fact

Lucentis to treat wet age-related macular degeneration (AMD)

An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.

Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Y. Chung, and Robert Y. Kim. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006; 355(14): 1419-31. http://content.nejm.org/cgi/content/abstract/355/14/1419

Reference

Title
Ranibizumab for Neovascular Age-Related Macular Degeneration
Publication
N Engl J Med
Publication Date
2006
Authors
Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Y. Chung, and Robert Y. Kim
Volume & Issue
Volume 355, Issue 14
Pages
1419-31
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.